KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Asset Writedowns and Impairment (2020 - 2025)

Boston Scientific (BSX) has disclosed Asset Writedowns and Impairment for 7 consecutive years, with $51.0 million as the latest value for Q4 2025.

  • Quarterly Asset Writedowns and Impairment fell 85.67% to $51.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $188.0 million through Dec 2025, up 135.0% year-over-year, with the annual reading at $124.0 million for FY2025, 67.88% down from the prior year.
  • Asset Writedowns and Impairment hit $51.0 million in Q4 2025 for Boston Scientific, up from $27.0 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $356.0 million in Q4 2024 to a low of -$246.0 million in Q3 2024.
  • Historically, Asset Writedowns and Impairment has averaged $65.3 million across 5 years, with a median of $48.0 million in 2021.
  • Biggest YoY gain for Asset Writedowns and Impairment was 1248.39% in 2024; the steepest drop was 24700.0% in 2024.
  • Year by year, Asset Writedowns and Impairment stood at $197.0 million in 2021, then crashed by 36.55% to $125.0 million in 2022, then tumbled by 124.8% to -$31.0 million in 2023, then surged by 1248.39% to $356.0 million in 2024, then tumbled by 85.67% to $51.0 million in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for BSX at $51.0 million in Q4 2025, $27.0 million in Q3 2025, and $356.0 million in Q4 2024.